IGF-1 LR3 – Comprehensive Research Overview (2026)

IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a synthetic analog of IGF-1 with an N-terminal 13-amino-acid extension and an Arg→Arg substitution at position 3. These modifications reduce binding to IGF-binding proteins (IGFBPs), dramatically extending its half-life from ~10 minutes (native IGF-1) to ~20–30 hours. IGF-1 LR3 is primarily researched for muscle growth, body composition, recovery, and metabolic effects. It is one of the most potent anabolic research peptides available.

→ View IGF-1 LR3 (for laboratory research use only)

Mechanism of Action

  • Binds IGF-1 receptors (IGF-1R) on muscle, adipose, bone, and other tissues.
  • Activates PI3K/Akt/mTOR pathway → protein synthesis, cell growth, and anti-apoptosis.
  • Promotes satellite cell activation and muscle fiber hyperplasia.
  • Enhances glucose uptake and nutrient partitioning toward muscle.
  • Reduced IGFBP binding means more free, bioactive IGF-1 reaching target tissues.

Clinical Evidence and Research Findings

Extensive preclinical data demonstrate potent anabolic, anti-catabolic, and metabolic effects. IGF-1 LR3 is widely used in cell culture and animal research for muscle biology, metabolic disease, and growth studies. Human clinical data are limited to native IGF-1 studies; LR3 is primarily a research tool. Its extended half-life makes it more practical for research protocols than native IGF-1.

→ Interested in researching IGF-1 LR3? View Product Options

Benefits (Research & Clinical Observations)

  • Potent muscle growth and hyperplasia
  • Enhanced fat loss and nutrient partitioning
  • Accelerated recovery from training and injury
  • Improved insulin sensitivity and glucose metabolism
  • Extended half-life for practical research dosing

Typical Dosing Protocols (Research)

  • Common protocols: 20–100 μg subcutaneous or intramuscular daily or every other day
  • Cycles: 4–8 weeks; longer cycles increase risk of receptor desensitization
  • Often used post-workout for nutrient partitioning effects

Safety Profile and Side Effects

Common side effects: hypoglycemia (most important risk — must be used with food/carbohydrates), injection-site reactions, potential for acromegalic effects with chronic high-dose use. Contraindicated in active cancer.

Monitoring recommended: Blood glucose, IGF-1 levels, and metabolic markers.

Summary

IGF-1 LR3 is a potent, long-acting IGF-1 analog with extensive research applications in muscle biology, metabolic science, and anabolic physiology. Its extended half-life and reduced IGFBP binding make it a superior research tool compared to native IGF-1. As with all compounds in this library, IGF-1 LR3 is not an approved drug and should only be considered under qualified medical supervision with glucose monitoring.

For Laboratory Research Use View IGF-1 LR3 →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.